ES2243273T3 - Utilizacion terapeutica de d-treo-metilfenidato para el tratamiento del trastorno de hperactividad y deficit de atencion. - Google Patents

Utilizacion terapeutica de d-treo-metilfenidato para el tratamiento del trastorno de hperactividad y deficit de atencion.

Info

Publication number
ES2243273T3
ES2243273T3 ES00940504T ES00940504T ES2243273T3 ES 2243273 T3 ES2243273 T3 ES 2243273T3 ES 00940504 T ES00940504 T ES 00940504T ES 00940504 T ES00940504 T ES 00940504T ES 2243273 T3 ES2243273 T3 ES 2243273T3
Authority
ES
Spain
Prior art keywords
mph
treatment
dose
study
methylphenidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00940504T
Other languages
English (en)
Spanish (es)
Inventor
Elizabeth Janina Celltech Pharma Ltd Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Celltech Pharma Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Pharma Europe Ltd filed Critical Celltech Pharma Europe Ltd
Application granted granted Critical
Publication of ES2243273T3 publication Critical patent/ES2243273T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ES00940504T 1999-06-09 2000-06-08 Utilizacion terapeutica de d-treo-metilfenidato para el tratamiento del trastorno de hperactividad y deficit de atencion. Expired - Lifetime ES2243273T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913458.7A GB9913458D0 (en) 1999-06-09 1999-06-09 The therapeutic use of d-threo-methylphenidate
GB9913458 1999-06-09

Publications (1)

Publication Number Publication Date
ES2243273T3 true ES2243273T3 (es) 2005-12-01

Family

ID=10855048

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00940504T Expired - Lifetime ES2243273T3 (es) 1999-06-09 2000-06-08 Utilizacion terapeutica de d-treo-metilfenidato para el tratamiento del trastorno de hperactividad y deficit de atencion.

Country Status (9)

Country Link
EP (1) EP1185268B1 (enExample)
JP (1) JP2003501387A (enExample)
AT (1) ATE302006T1 (enExample)
AU (1) AU766748B2 (enExample)
CA (1) CA2376215A1 (enExample)
DE (1) DE60022033T2 (enExample)
ES (1) ES2243273T3 (enExample)
GB (1) GB9913458D0 (enExample)
WO (1) WO2000074680A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
CA2595400C (en) 2005-01-20 2017-01-17 Institute For Molecular Medicine, Inc. Methylphenidate derivatives and their use in the treatment of angiogenic diseases and conditions
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
EP3349853B1 (en) 2015-09-15 2023-12-20 Praxis Bioresearch, LLC Prodrugs of fencamfamine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514451D0 (en) * 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
MX9805870A (enExample) * 1996-01-22 1999-01-31
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate

Also Published As

Publication number Publication date
WO2000074680A1 (en) 2000-12-14
EP1185268B1 (en) 2005-08-17
AU766748B2 (en) 2003-10-23
GB9913458D0 (en) 1999-08-11
ATE302006T1 (de) 2005-09-15
EP1185268A1 (en) 2002-03-13
DE60022033T2 (de) 2006-03-30
AU5543200A (en) 2000-12-28
JP2003501387A (ja) 2003-01-14
CA2376215A1 (en) 2000-12-14
DE60022033D1 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
ES3025836T3 (en) Use of pridopidine for treating functional decline
ES2610508T3 (es) Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
Ibach et al. Acetylcholinesterase inhibition in Alzheimer's Disease
ES3014558T3 (en) Devices and methods for drug administration and mixing, and training of proper techniques therefor
EP2288345B1 (en) Psycho-pharmaceuticals
BRPI0718323A2 (pt) Tratamento de transtornos invasivos do desenvolvimento.
ES2323451T7 (es) Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US20250108044A1 (en) Methods of treating depressive disorders
US20050187196A1 (en) Treatment of attention disorders
ES2709874T3 (es) Composiciones nootrópicas para mejorar el rendimiento de la memoria
CA2708323C (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
BR112020011345A2 (pt) tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
WO2008144665A1 (en) Use of pimavanserin in the treatment of parkinson and symptoms thereof
Varshneya et al. Structurally diverse fentanyl analogs yield differential locomotor activities in mice
Schweri et al. Biochemical and behavioral characterization of novel methylphenidate analogs
Griffin III et al. The interactive effects of methylphenidate and ethanol on ethanol consumption and locomotor activity in mice
EP1185268B1 (en) The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
BRPI0718318A2 (pt) Processos para tratamento de distúrbios de perturbação de comportamento.
US20230270720A1 (en) Mavoglurant, a mglur5 antagonist, for use in the treatment in the reduction of opioid use
US20090270373A1 (en) Treatment of down syndrom with benzodiazepine receptor antagonists
US20230372302A1 (en) Prophylaxis and reversal of stimulant and opioid/opiate overdose and/or toxic exposure
Garcia The Therapeutic Potential of Serotonin 1B Receptor Agonists for Treating Psychostimulant Use Disorders
BR112020004506A2 (pt) mazindol para uso no tratamento de distúrbio de uso de substâncias, composição compreendendo mazindol, método de tratamento de distúrbio de abuso de substâncias
Wooters The effects of oral methylphenidate on cocaine-induced hyperactivity and cocaine self-administration in a rodent model of ADHD